Streetbeat News

CHEK

Check-Cap Ltd.

Industry

Medical - Diagnostics & Research

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Open

0.81

Mkt cap

4.4M

Volume

2.2K

High

0.81

P/E Ratio

-0.25

52-wk high

3.52

Low

0.76

Div yield

N/A

52-wk low

0.76

Westport Fuel Systems Inc. (NASDAQ:WPRT) shares fell by approximately 10% after reporting a Q4 loss wider than expected. Other stocks experienced significant movements, with notable gainers including Stoke Therapeutics, Inc. (NASDAQ:STOK) and losers like Quhuo Limited (NASDAQ:QH). The movements were attributed to various factors including financial results, clinical trial data, and strategic agreements.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 5:45 pm

Check-Cap Ltd. (CHEK) shares are experiencing an uptick following the announcement of a definitive Business Combination Agreement with Nobul AI. This strategic move could potentially enhance Check-Cap's market position by integrating Nobul AI's technological advancements.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:27 pm

Nobul AI Corp has agreed to acquire Check-Cap Ltd (NASDAQ:CHEK), with Nobul shareholders becoming the majority holders of the combined company. The merger aims to create a public company focused on an AI-driven fintech marketplace and enhancing traditional companies through AI, headquartered in Toronto, Canada. The combined entity plans to apply for listing on the NASDAQ and TSX, with Nobul's executive team leading the new company. The acquisition is seen as a strategic move to deliver value to shareholders and leverage Nobul's M&A expertise. Check-Cap, a clinical-stage medical diagnostics company, is known for developing C-Scan, a preparation-free colorectal cancer screening test.

Portfolio Pulse from Vandana Singh

March 26, 2024 | 1:13 pm

Stoke Therapeutics, Inc. (STOK) shares surged by approximately 70% in pre-market trading following the announcement of positive Phase 1/2a data for STK-001 in Dravet syndrome. Other stocks also showed significant movement in pre-market trading, with notable gainers including Check-Cap Ltd. (CHEK), C3is Inc. (CISS), and OpGen, Inc. (OPGN), among others. On the losing end, NeuBase Therapeutics, Inc. (NBSE) and AppTech Payments Corp. (APCX) saw substantial declines.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 12:00 pm

Nobul AI Corp has entered into a business combination agreement with Check-Cap (CHEK) to form a North American technology company focused on an AI-driven fintech marketplace. The combined entity plans to apply for listings on both the Nasdaq and TSX stock exchanges.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 6:56 am

Check-Cap Ltd. received a termination notice from Keystone Dental regarding their previously agreed business combination. The agreement, dated August 16, 2023, involved Keystone, Capstone Dental Pubco, Capstone Merger Sub Ltd, and Capstone Merger Sub Corp.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 2:02 pm

Check-Cap Ltd. (CHEK) announced that the Israeli court has rejected all claims made by Symetryx against the company, including those related to alleged conflicts of interest of Check-Cap's Board of Directors in the Keystone business combination. The court also ordered Symetryx to pay Check-Cap's legal expenses. Check-Cap is addressing false statements made by Symetryx in a press release, clarifying that board member Yuval Yanai has no affiliation with Minerva Surgical and Exalenz Biosciences, contrary to Symetryx's claims.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 7:08 am

Institutional Shareholder Services (ISS) has recommended that shareholders of Check-Cap Ltd. (CHEK) vote in favor of the proposed business combination with Keystone Dental. This endorsement could influence shareholder approval for the merger, which is a significant step in the process of combining the two companies.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 6:59 pm

Yoav Kimchy, founder and former CTO of Check-Cap Ltd. (NASDAQ:CHEK), has issued an open letter urging shareholders to vote against the merger with Keystone Dental and in favor of the Symetryx Board of Directors nominees. Symetryx continues to advocate for voting against the Keystone Dental transaction, arguing it undervalues Check-Cap's intellectual property and does not maximize shareholder value. Symetryx has hired Mackenzie Partners, Inc. as an advisor and encourages shareholders to contact them for more information.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 8:56 pm

Symetryx, holding 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, issued an open letter urging shareholders to vote against the Keystone Dental merger and Check-Cap board nominees, citing an unrealistic valuation of Keystone and Check-Cap's troubling cash burn. Symetryx recommends voting for its own slate of director candidates, arguing that the proposed merger is value-destructive and dilutive, and that the Check-Cap board is not acting in shareholders' best interests. Symetryx also highlights ongoing operational concerns, including a deficiency letter from the FDA to Keystone, and criticizes the current board for not engaging with Symetryx's proposals or providing financial transparency.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.